SurvivorNet on MSN
Diagnosing muscle-invasive bladder cancer: The initial work-up
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine cytology), a cystoscopy to visualize the inside of the bladder, and/or a CT ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
Medindia on MSN
Blood in Urine? Why Early Scans Detect Bladder Cancer Faster
India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results